

ORIGINAL ARTICLE

Impact of Genetic Testing for Cardiomyopathy on Emotional Well-Being and Family Dynamics

A Study of Parents and Adolescents

Priyanka Ahimaz¹ MS, CGC; Maya Sabatello¹ LLB, PhD; Min Qian¹ PhD; Aijin Wang, MS; Erin M. Miller, MS, CGC; Ashley Parrott, MS, CGC; Ashwin K. Lal¹ MD; Kathryn C. Chatfield, MD; Joseph W. Rossano¹ MD; Stephanie M. Ware¹ MD, PhD; John J. Parent¹ MD; Paul Kantor¹ MD; Lisa Yue¹ MBA; Julia Wynn, MS, CGC, MS; Teresa M. Lee, MD; Linda J. Addonizio¹ MD; Paul S. Appelbaum¹ MD; Wendy K. Chung¹ MD, PhD

BACKGROUND: Genetic testing is indicated for children with a personal or family history of hereditary cardiomyopathy to determine appropriate management and inform risk stratification for family members. The implications of a positive genetic result for children can potentially impact emotional well-being. Given the nuances of cardiomyopathy genetic testing for minors, this study aimed to understand how parents involve their children in the testing process and investigate the impact of genetic results on family dynamics.

METHODS: A survey was distributed to participants recruited from the Children's Cardiomyopathy Foundation and 7 North American sites in the Pediatric Cardiomyopathy Registry. The survey explored adolescent and parent participants' emotions upon receiving their/their child's genetic results, parent-child result communication and its impact on family functionality, using the McMaster Family Assessment Device.

RESULTS: One hundred sixty-two parents of minors and 48 adolescents who were offered genetic testing for a personal or family history of cardiomyopathy completed the survey. Parents whose child had cardiomyopathy were more likely to disclose positive diagnostic genetic results to their child ($P=0.014$). Parents with unaffected children and positive predictive testing results were more likely to experience negative emotions about the result ($P\leq 0.001$) but also had better family functioning scores than those with negative predictive results ($P=0.019$). Most adolescents preferred results communicated directly to the child, but parents were divided about whether their child's result should first be released to them or their child.

CONCLUSIONS: These findings have important considerations for how providers structure genetic services for adolescents and facilitate discussion between parents and their children about results.

Key Words: behavior ■ cardiomyopathies ■ family ■ genetic testing ■ psychology

Cardiomyopathy is a heterogeneous heart disease that can vary in anatomy, age of onset, and associated symptoms. Pediatric cardiomyopathy has an annual incidence of 1 to 1.5 per 100 000 children.¹ It can be isolated or part of a syndrome that includes extracardiac features. There are currently over 100 genes that cause cardiomyopathies in children, many more than in adults,² and most of the causative genes are inherited

in an autosomal dominant manner.¹ Cardiomyopathy genetic testing (CGT) in children has utility to confirm a diagnosis, clarify prognosis, anticipate extracardiac manifestations, determine eligibility for disease-specific therapies or clinical trials, inform risk for other family members, and provide information to assist reproductive decisions.³⁻⁵ Identifying asymptomatic children at risk for cardiomyopathy facilitates appropriate surveillance and

Correspondence to: Wendy K. Chung, MD, PhD, Columbia University Irving Medical Center, 1150 St Nicholas Ave, Room 620, New York, NY 10032. Email wkc15@cumc.columbia.edu

The Data Supplement is available at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.120.003189>.

For Sources of Funding and Disclosures, see page 437.

© 2021 American Heart Association, Inc.

Circulation: Genomic and Precision Medicine is available at www.ahajournals.org/journal/circgen

Nonstandard Abbreviations and Acronyms

CGT	cardiomyopathy genetic testing
DGT	diagnostic genetic testing
PGT	predictive genetic testing
VUS	variant of uncertain significance

identification of early cardiac disease to guide medical management, including restrictions in physical activity and use of medications.^{4,6,7}

While there are benefits of CGT, the psychological impact of genetic results on families is understudied. This is especially true for adolescents, who are in a phase of life contending with issues of identity and autonomy. A study evaluating the well-being of children between the ages of 8 to 18 years with positive cardiac genetic testing showed that there was no difference in their overall psychological health compared with the control children group.⁸ However, previous studies of cancer genetic testing among minors identified psychosocial concerns involving family tensions that could arise from the genetic testing result.⁹ In one study, girls between 6 and 13 years of age with a family history of breast cancer had higher disease-specific distress than their peers, which was strongly associated with poorer family communication.¹⁰

Genetic testing in minors is complicated as parents are entrusted to provide consent for their testing, although some children and most adolescents are cognitively capable of understanding their results and their implications.¹¹ Issues of autonomy become increasingly important as adolescents age, yet existing laws require parental consent but not adolescents' consent.¹² Prior studies of adolescents who underwent diagnostic genetic testing (DGT) indicated a strong desire to be involved in the process of making decisions about testing and return of results.^{7,13,14} A recent study surveying adolescents with congenital heart disease and parents highlighted that the majority in both groups felt it was important for adolescents to know their genetic risk to prevent gaps in cardiac care as they transition to adulthood.¹⁵ Studies in other contexts of genetic testing suggest that parents desire to determine the time and manner of disclosing genetic results to their child,¹⁴ notwithstanding evidence that parents lack the necessary medical and genetic knowledge to discuss such information accurately with their child.^{8,16,17} Understanding of family dynamics can help medical providers facilitate result communication between the child and family.

Given the development of health practices and behaviors during formative years of childhood, it is important for adolescents' long-term compliance with medical care to understand the impact of CGT on themselves and their families and to develop effective methods to support them through the testing process. Our multicenter study aimed to better understand how families involve minors in the

genetic testing and result communication processes by conducting a survey of adolescents and parents of children who were offered CGT. We examined (1) how minors are involved in the genetic testing process, (2) family communication of genetic testing, and (3) the psychosocial impact of result disclosure on adolescents and parents.

METHODS

Detailed methodology is available in the Methods section in the [Data Supplement](#). The study was approved by the institutional review boards at each of 7 study sites that were part of the Pediatric Cardiomyopathy Registry and centrally at Columbia University. Informed consent and assent were obtained from all parent and adolescent participants, respectively.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

RESULTS

In total, 162 parents from unique families completed the parental survey. Eighty-one parent participants consented for their adolescent child to participate. Of those, 48 adolescents between the ages of 13 to 18 years completed the survey for an adolescent response rate of 59%. The number of participants in each subcohort based on type of participant and their clinical cardiomyopathy status is shown in Figure 1.

Parents

Demographic data from the 162 parent respondents included in this study are shown in Table 1. One hundred and fifty-four parents had a child who underwent CGT: 100 parents had a child who underwent DGT and were classified as group 1; the remaining 54 parents had a child who underwent predictive genetic testing (PGT) and were classified as group 2. The clinical and genetic test results for parent participants and their children are summarized in Table 2. Among the parents recruited from the hospitals, there was a 97.3% concordance rate between reported responses on their child's genetic test result and medical records; discordant responses were limited to 3 parents whose child had a variant of uncertain significance (VUS) but who reported positive results.

Communication With Children

While the majority of parents in both group 1 (n=70; 70%) and group 2 (n=41; 75.9%) reported their child was informed that they were going to have CGT, the proportion of parents who actively involved their child in the decision-making process to have testing was higher in group 1 (n=24; 24%) than in group 2 (n=7; 12.9%). See Table 1 in the [Data Supplement](#) for total responses on the involvement of children in the testing process.




Figure 1. Participant subcohorts.

Classification of subcohorts based on cardiomyopathy genetic testing status used for data analysis. *Independent parent indicates only a single parent was enrolled from each family.

Among the 100 parents in group 1, 88 were aware of and could recall their child's result at the time of the survey. The majority of these parents (n=62; 70.5%) reported they had communicated the result to their child, and this was strongly associated with the type of result (ie, positive/negative/VUS) received- 79.7% of parents of children with positive DGT results had disclosed results to their child compared with 57.1% with negative DGT results and 37.5% with VUS DGT results (P=0.014). Although the proportion of parents in group

2 who shared PGT results with their child was similar (n=31; 66%), there was no significant association between the parent-child communication of result and the type of result (P=0.591). Disclosure of results to the child was significantly associated with the child's age at testing in both group 1 (mean [interquartile range]=11 [8–13] years for disclosure versus 4 [1.5–10.5] years for nondisclosure; P=0.002) and group 2 (mean [interquartile range]=12 [9–13] years for disclosure versus 4 [0.375–9] for nondisclosure; P≤0.001).

Table 1. Demographics of Participants

Demographics of parent participants	N=162	Demographics of adolescent participants	N=48
Average age, y, at time of survey	41.5 (SD=7.3)	Average age, y, at time of survey	16.7 (SD=2.6)
Sex			
Male	65 (40.2%)	Male	24 (50%)
Female	97 (59.8%)	Female	24 (50%)
Race/ethnicity			
White	122 (75.3%)	White	41 (85.4%)
Hispanic	15 (9.2%)	Hispanic	3 (6.2%)
Asian or Pacific Islander	8 (5%)	Asian or Pacific Islander	2 (4.1%)
Black	5 (3%)	More than one race	2 (4.1%)
More than one race	4 (2.4%)		
Other	4 (2.4%)		
Native Hawaiian or other Pacific Islander	2 (1.2%)		
American Indian or Alaskan Native	1 (0.6%)		
Highest education completed			
Some high school	10 (6.2%)	Less than grade 8	10 (20.8%)
High school or GED	21 (13%)	Grade 9	10 (20.8%)
Some college/vocational school	31 (19.2%)	Grade 10	11 (22.9%)
College graduate	56 (34.5%)	Grade 11	9 (18.8%)
Master's degree	33 (20.3%)	Grade 12	3 (6.2%)
Doctoral degree	7 (4.3%)	Some college/vocational school	5 (10.4%)

Downloaded from <http://ahajournals.org> by on October 2, 2021

Table 2. Reported CM Status and Genetic Testing Results of Participants

Clinical and genetic testing status of parent participants (N=162)*				
Clinical status	Had CM genetic testing	Positive result	Negative result	Uncertain result
Diagnosed with CM (n=23)	22	19	1	2
Not diagnosed with CM (n=129)	60	21	21	18
Clinical and genetic testing status of child of parent participants (N=162)*				
Clinical status	Had CM genetic testing	Positive result	Negative result	Uncertain result
Child diagnosed with CM (n=103)	100	59	21	8
Child not diagnosed with CM (n=59)	54	24	21	2
Clinical and genetic testing status of adolescent participants (N=48)*				
Clinical status	Had CM genetic testing	Positive result	Negative result	Uncertain result
Diagnosed with CM (n=24)	21	13	1	3
Not diagnosed with CM (n=24)	20	4	11	2

CM indicates cardiomyopathy.

*N is discordant with response numbers because 10 parent participants did not answer if they were affected with cardiomyopathy, 19 parent participants did not know/could not recall their child's result, 7 adolescents did not know/could not recall their result.

†Uncertain result indicates variant of uncertain significance was identified.

Communication With Extended Family and Impact on Family Dynamics

Almost equal proportions of parents in group 1 did (n=37; 42%) and did not share (n=41; 46%) DGT results with the extended family, and the type of result obtained did not impact their sharing (Table 3). Among group 2, 72.3% (n=34) of parents shared PGT results with extended family, and a higher percentage of parents (88.3%) shared positive PGT results compared with negative PGT results (66.6%; $P=0.042$).

Of all 67 parents from groups 1 and 2 who shared results, only 6 parents (9%) reported that knowledge of results negatively impacted their family dynamics. These 6 parents all had a child with positive CGT results. The remaining respondents felt that the results did not affect the family (n=13; 19.4%), affected it positively (n=24; 35.8%), or were unsure if anything changed in their family dynamics (n=24; 35.8%).

The average McMaster family assessment device (MFAD) functionality score for group 1 was 1.9 (out of a maximum of 4), with average scores of 1.9, 1.8, and 1.8 for families with positive, negative, and VUS DGT results, respectively. A score of ≥ 2 indicates unhealthy family functioning. The genetic results of DGT were not significantly associated with how well a family functioned in group 1 (% healthy functioning families were 49%, 52%, and 49% for positive, negative, and VUS DGT results, respectively, $P=0.842$). The average McMaster family assessment device functionality score for group 2 was 1.7, with average scores of 1.6, 1.8, and 1.7 for families with positive, negative, and VUS PGT results, respectively. Among group 2, there was a significant difference in the functionality of families based on genetic results. Ninety-one percent (n=22) of families with positive PGT results met criteria for healthy family functionality while 57% (n=12) of families with negative PGT results and 100% (n=2) of families with VUS results met criteria for healthy functioning ($P=0.019$).

Feelings About Genetic Test Results

There was no significant association of feelings after receiving the child's result with the type of result in group 1 ($P=0.189$), although a majority of parents in this group expressed negative emotions after their child had a positive (n=38; 64.4%) or uncertain (n=5; 62.5%) DGT result (Figure 2). The responses of the 21 parents whose child had a negative DGT result were more varied, but the most commonly reported emotions were still negative. There was a significant association between the feelings of parents in group 2 and the type of result their child had ($P\leq 0.001$). The majority of parents whose child had a positive PGT result reported negative emotions (n=13; 61.9%) and inversely, the majority of parents whose child had a negative PGT result reported positive emotions (n=15; 62.5%).

We also investigated if cardiomyopathy status in the 135 parents who knew their child's genetic test result affected the way they felt about the result. Six (6.8%) of the 88 parents in group 1 had cardiomyopathy, and 14 (29.7%) of the 47 parents in group 2 had cardiomyopathy. There was no significant association between parental cardiomyopathy status and feelings about the child's genetic result for group 1 ($P=0.425$). However, there was a trend for significant association between parents' cardiomyopathy status in group 2 and their feelings about their child's result ($P=0.052$). In both groups 1 and 2, more parents who had cardiomyopathy had negative feelings about their child's result. Among group 1, 83.3% (n=5) of parents who had cardiomyopathy had negative feelings while 57.3% (n=47) of parents who did not have cardiomyopathy had negative feelings. Among group 2, 64.3% (n=9) of parents who had cardiomyopathy had negative feelings compared with 27.3% (n=9) of parents who did not have cardiomyopathy and had negative

Table 3. Parent Responses on Family Communication and Impact on Family Dynamics Correlated to Genetic Results

Group 1: Parents who knew child's DGT result (N=88)					
Result communication and impact on family	Negative results (N=21)	Positive results (N=59)	Uncertain* results (N=8)	Total (N=88)	P value
Communication with child					
Medium age of child at disclosure with whom results were shared (IQR)	11 (8–13)			10 (5–13)	0.002
Medium age of child at testing with whom results were not shared (IQR)	4 (1.5–10.5)			10 (5–13)	0.002
Communicated result to child	12 (57.1%)	47 (79.7%)	3 (37.5%)	62 (70.5%)	0.014
Did not communicate result to child	9 (42.9%)	12 (20.3%)	5 (62.5%)	26 (29.5%)	0.014
Communication with family					
Shared with other family	8 (38.1%)	26 (44%)	3 (37.5%)	37 (42%)	0.827
Did not share with other family	11 (52.1%)	25 (42.4%)	5 (62.5%)	41 (46.5%)	0.827
Unsure if it was shared	2 (9.5%)	8 (13.6%)	0 (0%)	10 (11.3%)	0.827
MFAD scores†					
Healthy functioning (<2)	11 (52.4%)	29 (49.2%)	3 (37.5%)	43 (48.9%)	0.842
Unhealthy functioning (≥2)	10 (47.6%)	30 (50.8%)	5 (62.5%)	45 (51.1%)	0.842
Average (SD)	1.832 (0.640)	1.923 (0.620)	1.839 (0.642)	1.894 (0.621)	0.842
Group 2: Parents who knew child's PGT result (N=47)					
Communication with and impact on family	Negative results (N=21)	Positive results (N=24)	Uncertain* results (N=2)	Total (N=47)	P value
Communication with child					
Median age of child at disclosure with whom results were shared (IQR)	12 (9–13)			10 (5.5–13)	<0.001
Medium age of child at testing with whom results were not shared (IQR)	4 (0.375–9)			10 (5.5–13)	<0.001
Communicated result to child	13 (61.9%)	17 (70.8%)	1 (50%)	31 (66%)	0.591
Did not communicate result to child	8 (38.1%)	7 (29.2%)	1 (50%)	16 (34%)	0.591
Communication with family					
Shared with other family	14 (66.7%)	20 (83.3%)	0 (0%)	34 (72.3%)	0.042
Did not share with other family	5 (23.8%)	4 (16.7%)	2 (100%)	11 (23.4%)	0.042
Unsure if it was shared	2 (9.5%)	0 (0%)	0 (0%)	2 (4.3%)	0.042
MFAD scores†					
Healthy functioning (<2)	12 (57.1%)	22 (91.7%)	2 (100%)	36 (76.6%)	0.019
Unhealthy functioning (≥2)	9 (42.9%)	2 (8.3%)	0 (0%)	11 (23.4%)	0.019
Average (SD)	1.886 (0.660)	1.630 (0.420)	1.708 (0.177)	1.748 (0.543)	
Group 3: Adolescents who knew their DGT result (N=17)					
Communication with and impact on family	Negative results (N=1)	Positive results (N=13)	Uncertain* results (N=3)	Total (N=17)	P value
Communication with family					
Shared with other family	1 (100%)	8 (61.5%)	2 (66.7%)	11 (64.7%)	1.000
Did not share with other family	0 (0%)	5 (38.4%)	1 (33.3%)	6 (35.3%)	1.000
MFAD scores†					
Healthy functioning (<2)	1 (100%)	11 (84.6%)	3 (100%)	15 (88.2%)	1.000
Unhealthy functioning (≥2)	0 (0%)	2 (15.4%)	0 (0%)	2 (11.8%)	1.000
Average (SD)	2.000 (NA)	1.697 (0.445)	1.083 (0.083)	1.593 (0.463)	
Group 4: Adolescents who knew their PGT result (N=17)					
Communication with and impact on family	Negative results (N=11)	Positive results (N=4)	Uncertain* results (N=2)	Total (N=17)	P value
Communication with family					
Shared with other family	5 (45.5%)	3 (75%)	2 (100%)	10 (58.8%)	0.464

(Continued)

Downloaded from <http://ahajournals.org> by on October 2, 2021

Table 3. Continued

Group 4: Adolescents who knew their PGT result (N=17)					
Communication with and impact on family	Negative results (N=11)	Positive results (N=4)	Uncertain* results (N=2)	Total (N=17)	P value
Did not share with other family	6 (54.5%)	1 (25%)	0 (0%)	7 (41.2%)	0.464
MFAD scores†					
Healthy functioning (<2)	7 (63.6%)	4 (100%)	0 (0%)	11 (64.7%)	0.063
Unhealthy functioning (≥2)	4 (36.4%)	0 (0%)	2 (100%)	6 (35.3%)	0.063
Average (SD)	1.780 (0.681)	1.729 (0.322)	2.129 (0.054)	1.809 (0.570)	

DGT indicates diagnostic genetic testing; IQR, interquartile range; MFAD, McMaster family assessment device; and PGT, predictive genetic testing.

*Uncertain result indicates variant of uncertain significance was identified.

†MFAD score refers to score from the G12 subscale of the MFAD.

feelings. See Table II in the [Data Supplement](#) for comparison of parental feelings towards their child's result with their own cardiomyopathy status.

Adolescents

A total of 48 participants completed the adolescent survey. The mean age was 16.7 years. The demographics are summarized in Table 1. Forty-one (85%) adolescent participants had undergone CGT. Twenty-one adolescents had DGT (group 3) and 20 adolescents had PGT (group 4). Table 2 summarizes the clinical and genetic test results for adolescent participants. Among adolescents recruited from the hospital sites, there was a 93.7% concordance between reported responses on their genetic test result and medical records with 3 participants who had a VUS reporting that they had positive results. Two of these participants' parents also misreported their child's VUS as a positive result in their parental survey responses. This indicates that these adolescents correctly reported the information given to them by their parents.

Communication With Family Members and Impact on Family Dynamics

While the majority (n=30; 80.4%) of the 41 adolescent participants who had CGT were informed they were having genetic testing during the pretest counseling before their sample collection, the number of adolescents who were actively involved in the decision-making process to have CGT was higher in group 3 (n=12; 57.5%) than in group 4 (n=4; 20%). See Table I in the [Data Supplement](#) for total responses on involvement of adolescents in the testing process.

A majority of the 34 adolescent participants from both groups 3 and 4 who knew their results reported that their results were shared with relatives (n=30; 88.2%) and 21 of those respondents (70%) said they were the ones who shared the results with other family members. The type of result was not significantly associated with sharing results ($P=1$ for group 3 and $P=0.464$ for group


4). Majority of our participants reported that adolescent patients are most likely to discuss their results with their mother (n=31; 64.5%), whereas fewer felt they would discuss results with their father (n=5; 10.4%), their doctor (n=5; 10.4%), their best friend (n=8; 6%), or someone else (n=1; 2.08%).

In response to whether knowledge of results affected dynamics in the 30 families that shared the adolescent's result with relatives, only 2 (6.6%) felt that it had made things worse. Both the participants who felt things were worse had positive results and one of them further commented that the knowledge increased stress levels, however, not knowing was far more harmful. The type of genetic test result was not significantly associated with family functioning for adolescents in groups 3 and 4 ($P=1$ for both). The average McMaster family assessment device score for group 3 was 1.59, and the average score for group 4 was 1.8.

Feelings About Genetic Test Results

Among the 21 adolescent participants in group 3, 17 could remember the result of their DGT at the time of the survey, and there was no significant association between type of result and emotions felt after learning of their result ($P=0.457$; Figure 2). Seventeen of the 20 adolescents in group 4 were aware of their results. While not significant, there was a trend of emotions being associated with type of result among this group ($P=0.089$); most of the 11 participants with negative PGT results felt positive emotions after learning their result (n=9; 81.8%). When comparing parental cardiomyopathy status with adolescents' feelings about their results, a significant association was noted for group 3 ($P=0.041$) but not for group 4 ($P=0.862$). Among group 3, the majority of adolescents (n=7; 63.7%) whose parents had cardiomyopathy reported negative feelings.

Overall, the most commonly reported feelings among adolescents in both Groups 3 and 4 before testing were negative (n=16; 47%) and neutral emotions (n=11; 32.3%) while fewer reported positive (n=4; 11.7%) and mixed (n=3; 8.8%) emotions. The most frequently reported posttest emotions were positive (n=13; 38.2%).



Figures 2. Feelings of participants correlated with type of genetic test result received, that is, positive results (pathogenic variant identified), negative result (no pathogenic variant identified), or variant of uncertain significance.

Feelings were classified into categories of positive (happy, glad etc), negative (sad, angry etc), and neutral (indifferent, curious etc). **A**, Reported feelings of parents in group 1 after receiving their child’s diagnostic genetic result. N=88; no significant association was seen between the feelings of parents and the type of result their child with cardiomyopathy had ($P=0.189$), although the majority of parents whose child had a positive (64.4%) or uncertain result (62.5%) reported negative feelings. **B**, Reported feelings of parents in group 2 after receiving their child’s predictive genetic result. N=47; there was a significant association between the feelings of parents and the type of result their child without cardiomyopathy had ($P\leq 0.001$). Most parents whose child had a negative result (61.9%) reported positive feelings and most parents whose child had a positive result (62.5%) reported negative feelings. **C**, Reported feelings of adolescents in group 3 after receiving their diagnostic genetic result. N=17; no significant correlations between feelings of adolescents with cardiomyopathy and their genetic test result ($P=0.457$). **D**, Reported feelings of adolescents in group 4 after receiving their predictive genetic result. N=17; no significant correlations between feelings of adolescents with cardiomyopathy and their genetic test result ($P=0.089$). Most with negative results (81.8%) reported positive feelings.

Most of the 8 participants who had negative feelings posttesting (n=5; 62.5%) reported that they now felt better about their results, and the remainder did not feel differently. Comparison of emotions in pretest and post-test result stages for adolescents is summarized in Table III in the [Data Supplement](#).

Of all 34 adolescent respondents with and without cardiomyopathy who were aware of their results, 31 (91.1%) were glad to know their results, 2 (5.8%) were not sure, and 1 (2.9%) did not answer the question.

Parent-Adolescent Comparisons

We asked all parent and adolescent participants (N=210) who they believed should receive results from CGT of children between the ages of 13 to 18 years (Figure 3). Fifty percent of parents (n=81) said that the parents should get the results first and the child later,

whereas 40.7% of parents (n=66) said that the child and the parents should receive results at the same time. The responses from adolescent participants were markedly different: 70.8% of adolescents (n=34) thought that the child and the parents should receive results at the same time. Only 16.6% (n=8) believed that the parents should get the child’s results first and the child later.

Parent and adolescent participants were then asked the minimum age at which they felt a child should have the autonomy to decide whether to pursue CGT for themselves (Figure 4). About 30.8% of parents (n=50) felt that the decision should be based on maturity rather than chronological age, and a similar number of parents (n=49; 30.2%) felt that 13 to 16 years is the age range at which someone should have the autonomy to decide if they want CGT. A higher proportion of adolescents (n=21; 43.7%) felt that the ability to decide to have CGT should be based on level of maturity and not age.




Figure 3. Parents vs adolescent responses about order and timing of genetic results disclosure.

All 210 parent and adolescent participants (including those who did not have genetic testing) were surveyed about preference for child's result disclosure. The 162 parents were split between parents getting the child's result first and the child later (50%) and the child and the parents receiving results at the same time (40.7%). Whereas the majority of adolescents (70.8%) felt the child and the parents should receive results at the same time and 16.6% believed that the parents should get the child's results first.

DISCUSSION

Due to the risk for sudden death with cardiomyopathy and the ability to initiate medical therapy with first signs of disease, it is recommended that genetic testing be considered for children with cardiomyopathy or a family history of hereditary cardiomyopathy¹⁸ to determine surveillance approaches and preventive measures to mitigate

risks. Compliance with medical recommendations is key to reducing the risk of serious health consequences but can be challenging, especially for adolescents who seek autonomy over aspects of their lives, including health and lifestyle choices and decisions about sports participation. It is important to better understand the impact of genetic testing on adolescents and investigate best practices to engage them in the decision-making process of genetic




Figure 4. Parents vs adolescent responses about the minimum age for autonomous decision-making about genetic testing.

All 210 parent and adolescent participants (including those who did not have genetic testing) were surveyed about the age at which they felt someone could autonomously decide to have genetic testing. Most parents were split between opinions of basing the decision on maturity rather than age (30.8%) and 13–16 y being the minimum age to make an independent decision (30.2%). A similar trend was observed in adolescents where many felt that the decision should be based on maturity rather than age (42.7%) or that the decision could be made at 13–16 y of age (22.9%).

testing for cardiomyopathy. Our study sought to recognize how minors are included in the pretest counseling process and identify how genetic testing impacts the emotions of parents and adolescents and the dynamics of their families.

Impact on Families

Our results show that families have different experiences depending on the clinical status of their child. Most parents whose child had cardiomyopathy had negative feelings about their child's DGT result, whether it was positive, negative, or uncertain. We also found that more parents who have cardiomyopathy are likely to feel negatively about their child's CGT results. Among adolescents with positive DGT results, there were more neutral feelings. This is in line with previous studies demonstrating that significant psychological distress is not significantly associated with positive genetic results in probands with cardiomyopathy given that a positive result currently does not typically alter prognosis or treatment for most individuals who already have a clinical diagnosis.^{19,20} Based on our findings, however, having a parent with cardiomyopathy may negatively impact the way adolescents feel about their DGT result. The parents' overall negative feelings may also be reflective of their own burden of caregiving as well as concern for the child's quality of life related to their cardiac disease rather than the test results.⁸ However, among parents of children with PGT, those whose child had a negative result reported predominantly positive emotions, while parents whose child had a positive PGT result were more likely to report negative emotions. This same pattern was seen in adolescents with PGT, indicating that emotions felt in response to the PGT results are related to whether or not the potential genetic risk for cardiomyopathy is present. Despite the differing emotions after receiving the test results, nearly all adolescents were glad they knew their results, regardless of the outcome. This is consistent with previous research showing low regret among minors over the decision to have CGT.²¹ It also supports work affirming that the knowledge from testing results can make adolescents feel empowered.^{7,9,22}

There was a significant and perhaps unexpected difference in level of healthy family functioning among families with children who had PGT that correlated with genetic test results. Families with positive PGT results had better functioning scores than families with negative PGT results. Considering that this group represents children without cardiomyopathy, it is reassuring to see that positive predictive results were not significantly associated with dysfunctional family dynamics. For the majority of families, the dynamics of the family were perceived by participants to be preserved or improved after knowledge of genetic test results. This is an important finding of the study as there is limited data on the impact of genetic testing on family dynamics.

Communication Among Family Members

The majority of families in our study reported good communication between parent and child in the pretesting and posttesting stages. In both parent groups, the child's age was significantly associated with the likelihood of the parent disclosing their result to them. There was also a significant trend for more parents to disclose results to their child with cardiomyopathy when the results were positive, perhaps because positive results may impact future reproductive decisions. Overall, our parent cohort stated that the strongest reason they would not disclose results to their child is that the knowledge might be stressful or anxiety-inducing for their child. Prior studies in the context of cardiac and noncardiac disease have shown that most parents desire to have conversations with their child about their genetic risk but feel they lack the skill to approach the subject.^{15–17,23} Other stated reasons have included lack of parental access to appropriate knowledge resources,²² preference for their child to receive genetic education from a medical provider,¹⁵ perceived risk of disease for the child,¹⁷ and distress between parents regarding making a unified decision about when to have such conversations with children.¹⁶ Medical providers should help facilitate communication about genetic health between parents and children. Standardized educational materials for parents to discuss information with their children would be helpful.

Autonomy

In general, adolescent and parent participants shared similar views about the age when a minor should make the decision to have genetic testing. Both weighed individual maturity level rather than chronological age. However, parents and adolescents expressed different opinions on who should be the first person to receive a child's genetic result. Most adolescent children would like to be informed of their results at the same time as their parents, demonstrating a desire to be treated equally about issues related to their health. At the same time, the fact that they did not feel the need to know results before their parents may indicate they value having the support of a parent when receiving results. The difference in parents' and adolescents' opinions regarding this is important to explore. Previous work has highlighted that the opportunity to make choices during the pretest counseling helps adolescents maintain empowerment and adapt better to information about health threats.²¹

Study Limitations

The study is limited by the modest sample size and demographically homogenous population of largely non-Hispanic, White participants. There may be important cultural differences in family dynamics and feelings about genetic results in other racial/ethnic groups.

Because most participants were enrolled retrospectively, the time period between receiving genetic results and completing the survey varied from a few months to a few years. It is possible that this time lag may have affected the ability to recall how they felt after receiving results. Future studies can prospectively investigate the impact of testing on families to better understand how time affects their experiences.

Most of the parents who participated had children who were affected with cardiomyopathy and had positive genetic test results; those families may have been more inclined to participate in a study of genetic testing.

Medical records could not be reviewed from the 46 parent respondents who were recruited through the Children's Cardiomyopathy Foundation, so their responses to clinical status and genetic testing questions were not confirmed.

Conclusion and Considerations for Practice

Genetic counselors and other health care providers who provide care to children undergoing CGT should consider taking a family centered approach to counseling. When feasible, including adolescents during results disclosure, is preferred. As parents may express concerns about their adolescent's age, maturity level, clinical status, and social stressors, discussion with genetic professionals can support families to optimize the timing of testing and utility of knowing this information.

A clear plan for how results will be disclosed should also be agreed upon during pretest counseling, including whether the adolescent will be present for the results disclosure at the same time as their parents. Providing adolescents and their parents information to understand the genetic results in stages over time is helpful, and parents can continue to reinforce key messages as children get older and are able to better understand how their lives are impacted. Exploring existing dynamics to identify a family member who is trusted and close to the adolescent can help facilitate these conversations. For our adolescent cohort, mothers were identified to be the best family member to discuss results with. Follow-up after results disclosure with the family is encouraged to address questions and identify misunderstanding of concepts.

Genetic testing can have implications for the patient and the family as a whole. It is important to understand how children and adolescents are involved when dealing with genetic testing in minors and the impact the results can have on the family. While our sample size is modest, it demonstrates the importance of engaging adolescents in conversations about their genetic health. Overall, our results suggest that genetic testing for cardiomyopathies in children and adolescents does not cause emotional harm to families or adversely impact family dynamics. Further research into the adolescent perspective on the

impact of genetic testing is needed and can be valuable in informing health care practitioners about how to best provide care to young adult patients.

ARTICLE INFORMATION

Received September 2, 2020; accepted May 6, 2021.

Affiliations

Division of Molecular Genetics, Department of Pediatrics (P.A., J.W., W.K.C.), Children's Cardiomyopathy Foundation (L.Y.), Division of Cardiology, Department of Pediatrics (T.M.L., L.J.A.), and Department of Medicine (W.K.C.), Columbia University Irving Medical Center. Center for Precision Medicine and Genomics, Division of Ethics, Departments of Medicine, Medical Humanities and Ethics (M.S.), Department of Biostatistics, Mailman School of Public Health (M.Q., A.W.), and Center for Research on Ethical, Legal and Social Implications of Psychiatric, Neurologic and Behavioral Genetics, Department of Psychiatry, Columbia University, New York, NY (P.S.A.). Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Heart Institute Cincinnati, OH (E.M.M.). The Heart Institute, Cincinnati Children's Hospital Medical Center, OH (A.P.). Primary Children's Hospital, University of Utah, Salt Lake City (A.K.L.). Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora (K.C.C.). Children's Hospital of Philadelphia, PA (J.W.R.). Departments of Pediatrics and Medical and Molecular Genetics (S.M.W.) and Department of Pediatrics (J.J.P.), Indiana University School of Medicine, Indianapolis. Stollery Children's Hospital, Edmonton, Alberta, Canada (P.K.).

Acknowledgments

We acknowledge Lindsey Elmore, CCRP and Alexis Ann McEntire, BS of Riley Hospital for Children, Sydney Reilly of Children's Hospital of Philadelphia, Judy Carle, MS of University of Utah and Amy Taylor, PhD of Children's Hospital Colorado for their assistance with patient recruitment.

Sources of Funding

The partial funding for this study was provided by the R01HL111459, K01HG008653, RM1HG007257, and Children's Cardiomyopathy Foundation.

Disclosures

None.

Supplemental Materials

Supplemental Methods
Supplemental Tables I–III
Supplemental Figure I
References^{24,25}

REFERENCES

- Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, Chung WK, Jefferies JL, Rossano JW, Castleberry CD, et al. Pediatric cardiomyopathies. *Circ Res*. 2017;121:855–873. doi: 10.1161/CIRCRESAHA.116.309386
- McNally EM, Barefield DY, Puckelwartz MJ. The genetic landscape of cardiomyopathy and its role in heart failure. *Cell Metab*. 2015;21:174–182. doi: 10.1016/j.cmet.2015.01.013
- Ware SM. Genetic diagnosis in pediatric cardiomyopathy: clinical application and research perspectives. *Prog Pediatr Cardiol*. 2011;31:99–102. doi: 10.1016/j.jpccard.2011.02.006
- Tomašov P, Minárik M, Zemánek D, Čadová P, Homolová S, Čurilka K, Pěnička M, Benešová L, Belšánová B, Gregor P, et al. Genetic testing in the management of relatives of patients with hypertrophic cardiomyopathy. *Folia Biol (Praha)*. 2014;60:28–34.
- Repetti GG, Toepfer CN, Seidman JG, Seidman CE. Novel therapies for prevention and early treatment of cardiomyopathies. *Circ Res*. 2019;124:1536–1550. doi: 10.1161/CIRCRESAHA.119.313569
- Aleksova N, Rutberg J, Green M, Haddad H. Genetic testing in cardiomyopathies: an update on indications and benefits. *Curr Opin Cardiol*. 2017;32:189–195. doi: 10.1097/HCO.0000000000000362
- Meulenkamp TM, Tibben A, Mollema ED, van Langen IM, Wiegman A, de Wert GM, de Beaufort ID, Wilde AA, Smets EM. Predictive genetic testing for cardiovascular diseases: impact on carrier children. *Am J Med Genet A*. 2008;146A:3136–3146. doi: 10.1002/ajmg.a.32592

8. Smets EM, Stam MM, Meulenkamp TM, van Langen IM, Wilde AA, Wiegman A, de Wert GM, Tibben A. Health-related quality of life of children with a positive carrier status for inherited cardiovascular diseases. *Am J Med Genet A*. 2008;146A:700–707. doi: 10.1002/ajmg.a.32218
9. Duncan RE, Gillam L, Savulescu J, Williamson R, Rogers JG, Delatycki MB. “You’re one of us now”: young people describe their experiences of predictive genetic testing for Huntington disease (HD) and familial adenomatous polyposis (FAP). *Am J Med Genet C Semin Med Genet*. 2008;148C:47–55. doi: 10.1002/ajmg.c.30158
10. John EM, Terry MB, Keegan TH, Bradbury AR, Knight JA, Chung WK, Frost CJ, Lilge L, Patrick-Miller L, Schwartz LA, et al. The LEGACY girls study: growth and development in the context of breast cancer family history. *Epidemiology*. 2016;27:438–448. doi: 10.1097/EDE.0000000000000456
11. Bush LW, Bartoshesky LE, David KL, Wilfond B, Williams JL, Holm IA; ACMG SELI committee. Pediatric clinical exome/genome sequencing and the engagement process: encouraging active conversation with the older child and adolescent: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2018;20:692–694. doi: 10.1038/gim.2018.36
12. Botkin JR, Belmont JW, Berg JS, Berkman BE, Bombard Y, Holm IA, Levy HP, Ormond KE, Saal HM, Spinner NB, et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. *Am J Hum Genet*. 2015;97:6–21. doi: 10.1016/j.ajhg.2015.05.022
13. Hufnagel SB, Martin LJ, Cassidy A, Hopkin RJ, Antommaria AH. Adolescents’ preferences regarding disclosure of incidental findings in genomic sequencing that are not medically actionable in childhood. *Am J Med Genet A*. 2016;170:2083–2088. doi: 10.1002/ajmg.a.37730
14. McGowan ML, Prows CA, DeJonckheere M, Brinkman WB, Vaughn L, Myers MF. Adolescent and parental attitudes about return of genomic research results: focus group findings regarding decisional preferences. *J Empir Res Hum Res Ethics*. 2018;13:371–382. doi: 10.1177/1556264618776613
15. Crawford CA, Vujakovich CE, Elmore L, Fleming E, Landis BJ, Spoonamore KG, Ware SM. Adolescents with congenital heart defects: a patient and parental perspective of genetic information and genetic risk. *Cardiol Young*. 2020;30:219–226. doi: 10.1017/S1047951119002646
16. Valdez JM, Walker B, Ogg S, Gattuso J, Alderfer MA, Zelle K, Ford CA, Baker JN, Mandrell BN, Nichols KE. Parent-child communication surrounding genetic testing for Li-Fraumeni syndrome: living under the cloud of cancer. *Pediatr Blood Cancer*. 2018;65:e27350. doi: 10.1002/pbc.27350
17. Shah LL, Daack-Hirsch S. Family communication about genetic risk of hereditary cardiomyopathies and arrhythmias: an integrative review. *J Genet Couns*. 2018;27:1022–1039. doi: 10.1007/s10897-018-0225-9
18. Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, Morales A, Taylor MRG, Vatta M, Ware SM. Genetic evaluation of cardiomyopathy—A Heart Failure Society of America Practice Guideline. *J Card Fail*. 2018;24:281–302. doi: 10.1016/j.cardfail.2018.03.004
19. Aatre RD, Day SM. Psychological issues in genetic testing for inherited cardiovascular diseases. *Circ Cardiovasc Genet*. 2011;4:81–90. doi: 10.1161/CIRCGENETICS.110.957365
20. Wade CH, Wilfond BS, McBride CM. Effects of genetic risk information on children’s psychosocial wellbeing: a systematic review of the literature. *Genet Med*. 2010;12:317–326. doi: 10.1097/GIM.0b013e3181de695c
21. Pichini A, Shuman C, Sappleton K, Kaufman M, Chitayat D, Babul-Hirji R. Experience with genetic counseling: the adolescent perspective. *J Genet Couns*. 2016;25:583–595. doi: 10.1007/s10897-015-9912-y
22. MacLeod R, Beach A, Henriques S, Knopp J, Nelson K, Kerzin-Storarr L. Experiences of predictive testing in young people at risk of Huntington’s disease, familial cardiomyopathy or hereditary breast and ovarian cancer. *Eur J Hum Genet*. 2014;22:396–401. doi: 10.1038/ejhg.2013.143
23. Metcalfe A, Plumridge G, Coad J, Shanks A, Gill P. Parents’ and children’s communication about genetic risk: a qualitative study, learning from families’ experiences. *Eur J Hum Genet*. 2011;19:640–646. doi: 10.1038/ejhg.2010.258
24. Boterhoven de Haan KL, Hafekost J, Lawrence D, Sawyer MG, Zubrick SR. Reliability and validity of a short version of the general functioning subscale of the McMaster Family Assessment Device. *Fam Process*. 2015;54:116–123. doi: 10.1111/famp.12113
25. Miller W, Epstein NB, Bishop DS, Keitner GI. The McMaster family assessment device: reliability and validity. *JMFT*. 1985;11:345–356.